The 7 major chronic refractory cough markets reached a value of US$ 9.4 Billion in 2023. Looking forward, the publisher expects the 7MM to reach US$ 14.1 Billion by 2034, exhibiting a growth rate (CAGR) of 4.61% during 2023-2034.
The chronic refractory cough market has been comprehensively analyzed in this report titled "Chronic Refractory Cough Market: Epidemiology, Industry Trends, Share, Size, Growth, Opportunity, and Forecast 2024-2034". Chronic refractory cough (CRC) is a condition in which a person experiences a persistent cough that lasts for more than eight weeks despite undergoing multiple treatments. The disease can significantly affect an individual's quality of life, causing sleep disturbances, fatigue, and social isolation. The main symptom of this illness includes a dry, irritated cough localized around the laryngeal area. Other common indications of CRC involve globus, dyspnea, dysphonia, dizziness, persistent chest pain, night sweats, and physical complications, such as urinary incontinence, fractured ribs, muscle strain, etc. The diagnosis of this condition typically requires the identification of a patient's clinical features, medical history, and physical exam. A blood workup and allergy test can be utilized to evaluate signs of infection or other environmental factors that could be causing underlying symptoms. The healthcare provider may also perform spirometry or pulmonary function tests, which help determine lung functionality by measuring airflow in and out of the lungs. Additionally, laryngeal examination using flexible nasendoscopy, that detects the existence of laryngeal lesions or atypical motor patterns contributing to disease symptoms and laryngeal discomfort, is recommended among patients.
The increasing incidences of respiratory tract disorders secondary to sensory nerve damage caused by viral infections, inflammation, allergic factors, etc., are primarily driving the chronic refractory cough market. Besides this, the rising prevalence of various associated risk factors, including smoking, acid reflux, asthma, exposure to irritants, etc., which can irritate the airways, is also bolstering the market growth. Furthermore, the widespread adoption of neuro-modulating agents, like gabapentin and amitriptyline, since they act on the heightened neural sensitization that is linked with the pathogenesis of CRC, is creating a positive outlook for the market. Apart from this, the escalating utilization of non-pharmacological interventions, such as cough-suppression physiotherapy and speech therapy in patients who have failed or not responded to conventional medicinal regimens, is also augmenting the market growth. Additionally, the emerging popularity of superior laryngeal nerve block as a long-term treatment alternative, owing to its numerous advantages, including high patient compliance, feasibility, safety, and improved quality of life, is further expected to drive the chronic refractory cough market in the coming years.
This report provides an exhaustive analysis of the chronic refractory cough market in the United States, EU5 (Germany, Spain, Italy, France, and United Kingdom) and Japan. This includes treatment practices, in-market, and pipeline drugs, share of individual therapies, market performance across the seven major markets, market performance of key companies and their drugs, etc. The report also provides the current and future patient pool across the seven major markets. According to the report the United States has the largest patient pool for chronic refractory cough and also represents the largest market for its treatment. Furthermore, the current treatment practice/algorithm, market drivers, challenges, opportunities, reimbursement scenario and unmet medical needs, etc. have also been provided in the report. This report is a must-read for manufacturers, investors, business strategists, researchers, consultants, and all those who have any kind of stake or are planning to foray into the chronic refractory cough market in any manner.
The chronic refractory cough market has been comprehensively analyzed in this report titled "Chronic Refractory Cough Market: Epidemiology, Industry Trends, Share, Size, Growth, Opportunity, and Forecast 2024-2034". Chronic refractory cough (CRC) is a condition in which a person experiences a persistent cough that lasts for more than eight weeks despite undergoing multiple treatments. The disease can significantly affect an individual's quality of life, causing sleep disturbances, fatigue, and social isolation. The main symptom of this illness includes a dry, irritated cough localized around the laryngeal area. Other common indications of CRC involve globus, dyspnea, dysphonia, dizziness, persistent chest pain, night sweats, and physical complications, such as urinary incontinence, fractured ribs, muscle strain, etc. The diagnosis of this condition typically requires the identification of a patient's clinical features, medical history, and physical exam. A blood workup and allergy test can be utilized to evaluate signs of infection or other environmental factors that could be causing underlying symptoms. The healthcare provider may also perform spirometry or pulmonary function tests, which help determine lung functionality by measuring airflow in and out of the lungs. Additionally, laryngeal examination using flexible nasendoscopy, that detects the existence of laryngeal lesions or atypical motor patterns contributing to disease symptoms and laryngeal discomfort, is recommended among patients.
The increasing incidences of respiratory tract disorders secondary to sensory nerve damage caused by viral infections, inflammation, allergic factors, etc., are primarily driving the chronic refractory cough market. Besides this, the rising prevalence of various associated risk factors, including smoking, acid reflux, asthma, exposure to irritants, etc., which can irritate the airways, is also bolstering the market growth. Furthermore, the widespread adoption of neuro-modulating agents, like gabapentin and amitriptyline, since they act on the heightened neural sensitization that is linked with the pathogenesis of CRC, is creating a positive outlook for the market. Apart from this, the escalating utilization of non-pharmacological interventions, such as cough-suppression physiotherapy and speech therapy in patients who have failed or not responded to conventional medicinal regimens, is also augmenting the market growth. Additionally, the emerging popularity of superior laryngeal nerve block as a long-term treatment alternative, owing to its numerous advantages, including high patient compliance, feasibility, safety, and improved quality of life, is further expected to drive the chronic refractory cough market in the coming years.
This report provides an exhaustive analysis of the chronic refractory cough market in the United States, EU5 (Germany, Spain, Italy, France, and United Kingdom) and Japan. This includes treatment practices, in-market, and pipeline drugs, share of individual therapies, market performance across the seven major markets, market performance of key companies and their drugs, etc. The report also provides the current and future patient pool across the seven major markets. According to the report the United States has the largest patient pool for chronic refractory cough and also represents the largest market for its treatment. Furthermore, the current treatment practice/algorithm, market drivers, challenges, opportunities, reimbursement scenario and unmet medical needs, etc. have also been provided in the report. This report is a must-read for manufacturers, investors, business strategists, researchers, consultants, and all those who have any kind of stake or are planning to foray into the chronic refractory cough market in any manner.
Time Period of the Study
- Base Year: 2023
- Historical Period: 2018-2023
- Market Forecast: 2024-2034
Countries Covered
- United States
- Germany
- France
- United Kingdom
- Italy
- Spain
- Japan
Analysis Covered Across Each Country
- Historical, current, and future epidemiology scenario
- Historical, current, and future performance of the chronic refractory cough market
- Historical, current, and future performance of various therapeutic categories in the market
- Sales of various drugs across the chronic refractory cough market
Competitive Landscape:
This report also provides a detailed analysis of the current chronic refractory cough marketed drugs and late-stage pipeline drugs.In-Market Drugs
- Drug Overview
- Mechanism of Action
- Regulatory Status
- Clinical Trial Results
- Drug Uptake and Market Performance
Late-Stage Pipeline Drugs
- Drug Overview
- Mechanism of Action
- Regulatory Status
- Clinical Trial Results
- Drug Uptake and Market Performance
Key Questions Answered in this Report:
Market Insights
- How has the chronic refractory cough market performed so far and how will it perform in the coming years?
- What are the markets shares of various therapeutic segments in 2023 and how are they expected to perform till 2034?
- What was the country-wise size of the chronic refractory cough market across the seven major markets in 2023 and what will it look like in 2034?
- What is the growth rate of the chronic refractory cough market across the seven major markets and what will be the expected growth over the next ten years?
- What are the key unmet needs in the market?
Epidemiology Insights
- What is the number of prevalent cases (2018-2034) of chronic refractory cough across the seven major markets?
- What is the number of prevalent cases (2018-2034) of chronic refractory cough by age across the seven major markets?
- What is the number of prevalent cases (2018-2034) of chronic refractory cough by gender across the seven major markets?
- How many patients are diagnosed (2018-2034) with chronic refractory cough across the seven major markets?
- What is the size of the chronic refractory cough patient pool (2018-2023) across the seven major markets?
- What would be the forecasted patient pool (2024-2034) across the seven major markets?
- What are the key factors driving the epidemiological trend of chronic refractory cough?
- What will be the growth rate of patients across the seven major markets?
Chronic Refractory Cough: Current Treatment Scenario, Marketed Drugs and Emerging Therapies
- What are the current marketed drugs and what are their market performance?
- What are the key pipeline drugs and how are they expected to perform in the coming years?
- How safe are the current marketed drugs and what are their efficacies?
- How safe are the late-stage pipeline drugs and what are their efficacies?
- What are the current treatment guidelines for chronic refractory cough drugs across the seven major markets?
- Who are the key companies in the market and what are their market shares?
- What are the key mergers and acquisitions, licensing activities, collaborations, etc. related to the chronic refractory cough market?
- What are the key regulatory events related to the chronic refractory cough market?
- What is the structure of clinical trial landscape by status related to the chronic refractory cough market?
- What is the structure of clinical trial landscape by phase related to the chronic refractory cough market?
- What is the structure of clinical trial landscape by route of administration related to the chronic refractory cough market?
Table of Contents
1 Preface3 Executive Summary6 Patient Journey9 Chronic Refractory Cough - Unmet Needs10 Chronic Refractory Cough - Key Endpoints of Treatment13. Chronic Refractory Cough - Attribute Analysis of Key Marketed and Pipeline Drugs16 Chronic Refractory Cough - Recent Events and Inputs From Key Opinion Leaders18 Chronic Refractory Cough Market - Strategic Recommendations19 Appendix
2 Scope and Methodology
4 Chronic Refractory Cough - Introduction
5 Chronic Refractory Cough - Disease Overview
7 Chronic Refractory Cough - Epidemiology and Patient Population
8 Chronic Refractory Cough - Treatment Algorithm, Guidelines, and Medical Practices
11 Chronic Refractory Cough - Marketed Products
12 Chronic Refractory Cough - Pipeline Drugs
14. Chronic Refractory Cough - Clinical Trial Landscape
15 Chronic Refractory Cough - Market Scenario
17 Chronic Refractory Cough Market - SWOT Analysis
Methodology
LOADING...
Table Information
Report Attribute | Details |
---|---|
No. of Pages | 132 |
Published | May 2024 |
Forecast Period | 2023 - 2034 |
Estimated Market Value ( USD | $ 9.4 Billion |
Forecasted Market Value ( USD | $ 14.1 Billion |
Compound Annual Growth Rate | 3.8% |
Regions Covered | Global |